Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy  by Bond, R. et al.
Systematic review of randomized controlled trials
of patch angioplasty versus primary closure and
different types of patch materials during carotid
endarterectomy
R. Bond, MBBS, Dphil, FRCS,a K. Rerkasem, MD, FICS,b A. R. Naylor, MD, FRCS,c A. F. AbuRahma,
MD, FRCS,d and P. M. Rothwell, MD, PhD, FRCP,a Oxford, Southampton, and Leicester, United Kingdom;
and Charleston, W Va
Background: Patch angioplasty during carotid endarterectomy (CEA) may reduce the risk for perioperative or late carotid
artery recurrent stenosis and subsequent ischemic stroke. We performed a systematic review of randomized controlled
trials to assess the effect of routine or selective carotid patch angioplasty compared with CEA with primary closure, and
the effect of different materials used for carotid patch angioplasty.
Methods:Randomized trials were included if they compared carotid patch angioplasty with primary closure in any patients
undergoing CEA or use of one type of carotid patch with another.
Results: Thirteen eligible randomized trials were identified. Seven trials involving 1281 operations compared primary
closure with routine patch closure, and 8 trials with 1480 operations compared different patch materials (2 studies
compared both). Patch angioplasty was associated with a reduction in risk for stroke of any type (P  .004), ipsilateral
stroke (P  .001), and stroke or death during both the perioperative period (P  .007) and long-term follow-up (P 
.004). Patching was also associated with reduced risk for perioperative arterial occlusion (P  .0001) and decreased
recurrent stenosis during long-term follow-up (P < .0001). Seven trials that compared different patch types showed no
difference in the risk for stroke, death, or arterial recurrent stenosis either perioperatively or at 1-year follow-up. One
study of 180 patients (200 arteries) compared collagen-impregnated Dacron (Hemashield) patches with polytetrafluo-
roethylene patches. There was a significant increase in risk for stroke (P  .02), combined stroke and transient ischemic
attack (P .03), and recurrent stenosis (P .01) at 30 days, and an increased risk for late recurrent stenosis greater than
50% (P < .001) associated with Dacron compared with polytetrafluoroethylene.
Conclusions: Carotid patch angioplasty decreases the risk for perioperative death or stroke, and long-term risk for
ipsilateral ischemic stroke. More data are required to establish differences between various patch materials. ( J Vasc Surg
2004;40:1126-35.)Carotid endarterectomy (CEA) was shown in large
randomized controlled trials (RCTs) to reduce the risk for
stroke in selected patients with internal carotid artery ste-
nosis.1-3 Although the basic aims of surgery are always the
same, the exact techniques used to achieve them may vary
between surgeons.4 For example, carotid patch angioplasty
with either a vein or synthetic patch is believed by some
surgeons to be preferable to primary closure, because it may
reduce the risk for early and late recurrent stenosis and
consequently the long-term risk for ipsilateral ischemic
stroke.
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1126There are relatively few good prospective studies of
recurrent stenosis after CEA. Furthermore, those studies
that do exist are difficult to compare, because of differences
in the definition of recurrent stenosis and duration of
follow-up. However, it appears that carotid recurrent ste-
nosis greater than 50% diameter reduction, as detected on
duplex ultrasound scans, occurs in 6% to 36% of patients
during long-term follow-up,5,6 with most occurring in the
first 2 years after surgery.7 Carotid patch angioplasty may
reduce the risk for recurrent stenosis, and thus reduce the
long-term risk for recurrent ipsilateral ischemic stroke.8,9
However, the true value of reducing the rate of recurrent
stenosis is uncertain, because the risk for symptomatic
recurrent stenosis appears to be much lower than for all
recurrent stenosis, about 2% to 4%.7,10,11 Furthermore,
patch angioplasty may also be associated with certain peri-
operative risks, such as routine patching involving longer
carotid occlusion time, 2 suture lines instead of 1, and patch
material, all of which may increase the risk for postoperative
occlusion, arterial rupture, infection, or pseudoaneurysm
formation.8
There is considerable debate over the choice of patch
material. Vein patches, usually harvested from the saphe-
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by some, on the basis that they may be better at preventing
stroke or death.12 Vein also has the advantage of being
easily available and easy to handle, and having greater
resistance to infection. However, there may be morbidity
associated with vein harvesting, such as neuralgia, hemor-
rhage, and infection. Synthetic material, such as Dacron or
polytetrafluoroethylene (PTFE), is favored by others, who
believe it offers a lower risk for patch rupture13 and aneu-
rysm dilatation.14 It also spares the morbidity associated
with saphenous vein harvesting, and leaves the vein intact
for future use as a conduit for coronary or peripheral bypass
grafting. Furthermore, it is possible that one type of syn-
thetic material is better than another. For example, Abu-
Rahma et al15,16 found that PTFE was associated with
significantly fewer perioperative carotid thromboses and
strokes, compared with collagen-impregnated Dacron
(Hemashield) patches. Finally, a number of new materials,
such as bovine pericardium,17 are being introduced, but
have yet to be widely tested or accepted.
There is considerable heterogeneity in frequency of use
of patch angioplasty at the individual surgeon, national,
and international levels.4 Given the uncertainty implied by
such variation in practice, it is clearly important to establish
whether routine or selective patching is more effective than
and as safe as primary closure. RCTs provide the most
reliable evidence on which to base these assessments. We
therefore performed a systematic review of all such trials
that compared routine or selective patching with primary
closure, or the efficacy of various patch materials.
METHODS
The reviewers sought to identify all randomized trials
that compared primary closure with either routine (patch-
ing attempted in all patients) or selective carotid patch
angioplasty with any type of patch, and trials in which one
type of patch was compared with another. Trials in which
allocation to different treatment regimens was not ade-
quately concealed (eg, allocation by alternation, date of
birth, hospital number, day of the week, or with an open
random number list) were included in the main analyses,
but were also analyzed separately from those trials in which
allocation concealment was secure, to check that no bias
was being introduced by foreknowledge of treatment allo-
cation.18
Trials that included any patients undergoing CEA were
considered eligible, whether the initial indication for end-
arterectomy was symptomatic or asymptomatic carotid dis-
ease. We aimed to extract from each trial the number of
patients originally allocated to each treatment group, to
allow intention-to-treat analysis. End points were 30-day
risk for stroke, fatal stroke, all-cause death, and combined
stroke and death. Local complications, such as arterial
rupture, acute carotid thrombosis, wound infection, cranial
nerve injury, return to the operating room for any reason,
or development of recurrent stenosis greater than 50%,
were also recorded.To identify all relevant trials between 1980 and 2004,
we searched theMEDLINE and Embase databases, and the
Cochrane Controlled Trials Register, using a Medical Sub-
ject Headings (MeSH) strategy initially developed by the
Cochrane controlled trials group. Furthermore, 9 journals
were hand-searched for the same period:Annals of Surgery,
British Journal of Surgery, European Journal of Vascular
and Endovascular Surgery, Stroke, Journal of Vascular Sur-
gery, Annals of Vascular Surgery, American Journal of Sur-
gery, World Journal of Surgery, andCardiovascular Surgery.
The reference lists from all relevant trials identified with the
above methods were also searched, and the abstracts of the
following meetings were reviewed: The European Stroke
Conference, American Heart Association Stroke Confer-
ence, annual general meeting (AGM) of the Vascular Sur-
gical Society (United Kingdom), AGM of the Association
of Surgeons of Great Britain and Ireland, and the Annual
Meeting of the Society for Vascular Surgery (United
States). Two reviewers (R.B., K.R.) independently selected
which trials to include in the review. Disagreements were
resolved by discussion, and when necessary by arbitration
from a third reviewer (P.R.). The same 2 reviewers also
assessed the methodologic quality of each trial. Data on the
number of outcome events in all patients originally ran-
domized were sought to allow intention-to-treat analysis.
All data were independently extracted by 2 reviewers (R.B.,
K.R.) and cross-checked. In addition, details about the
patients included in the trial, inclusion and exclusion crite-
ria, comparability of the treatment and control groups for
important prognostic factors, type of patch, type of anes-
thetic, use of shunts, and use of anti-platelet therapy during
follow-up were also extracted. If any of these data were not
available from the publication, further information was
sought by correspondence with the trialists. However, re-
sponses were not always received.
Analysis of outcomes was performed per artery rather
than per patient, because this was howmost trials presented
their results. All of the trials included patients who had
undergone bilateral CEA, and in most the artery was ran-
domized to a particular procedure rather than the patient.
In these trials it was therefore possible for a patient to have
primary closure on 1 side and carotid patching on the other
side. In the reporting of these trials the results were given
for each artery randomized, rather than for each individual
patient. This makes sense for arterial complications such as
hemorrhage or occlusion, for ipsilateral events, and for
complications within 30 days of surgery, inasmuch as most
patients waited at least this long between first and second
operations, but is not ideal for patient-related long-term
clinical outcome events such as death or any stroke. We
therefore also performed intention-to-treat analysis per pa-
tient by requesting data from the authors about actual
numbers of patients treated. Because the number of bilat-
eral operations was small, there were no significant differ-
ences between the 2 analyses, and the per patient analyses
are not included here.
Proportional risk reductions were calculated on the
basis of a weighted estimate of the odds ratio, with the Peto
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odds ratios quoted are similar to the relative risk. Absolute
risk reductions were calculated from the crude risk for each
outcome in all trials combined. Heterogeneity between
trial results was tested with the standard 2 test.
RESULTS
Fourteen RCTs that fulfilled the eligibility criteria were
identified,14,15,19-31 (Ricco, unpublished data, 1997) but 1
unpublished trial was excluded because of excessive rates of
crossovers between randomized groups.31 The method-
ologic quality of the 13 included trials varied. For example,
inadequate methods of randomization and blinding were
used in several trials, and this could have biased the re-
sults.18 Most trials used sealed envelopes as the method of
randomization, but in 1 case the envelopes were not num-
bered or opaque,24 and in 2 trials allocation was made on
the basis of the patient’s hospital number22 or Social Secu-
rity number.26
Most of the patients in all of the trials received anti-
platelet or anticoagulant drugs long term after the opera-
tion, and all trials used heparin during the operation. How-
ever, 1 trial used heparin reversal at the end of surgery in
30% of patients with synthetic closure but in no patients
with vein closure.26 Data on heparin reversal were not
available from any of the other trials. During follow-up,
recurrent stenosis of the arteries was assessed with duplex
ultrasound scanning in all trials, with the addition of intra-
venous digital subtraction angiography in 2 trials.15,22
Trials of routine patch versus primary closure.
Seven trials compared routine patching with primary clo-
sure. Three trials used only saphenous vein patches,22-24
and 1 trial used only PTFE patches.20 Three trials used
both vein and synthetic (PTFE or Dacron) patches,19,21,25
but in 1 of these the results were not recorded by type of
patch that the patient received.19 One of the trials included
a group that was allocated to obligate patching without
randomization23; this group of patients was not included in
the analyses. Three trials excluded patients if the arteries
were thought too small to close primarily. Myers et al23
excluded 38 arteries if the vessels were less than 5 mm in
diameter, Katz and Kohl26 excluded 1 of 110 arteries less
than 3.5 mm in diameter, and AbuRahma et al21 excluded
12 of 399 arteries less than 4 mm in diameter. A summary
of all meta-analysis results is provided in Fig 1. Data from 7
trials (1193 patients, 1281 operations) were included in
this review.19-25
Outcomes within 30 days of operation. The overall
risk for stroke was 3.2%, and for combined stroke and death
was 3.5%. Patching was associated with a significant reduc-
tion in risk for any perioperative stroke (odds ratio [OR],
0.33; 95% confidence interval [CI], 0.20-0.71; P  .004),
ipsilateral stroke (OR. 0.32; 95% CI, 0.16-0.68; P  .001;
Fig 2), combined stroke or death (OR, 0.39; 95% CI,
0.20-0.78; P  .007; Fig 2), perioperative arterial occlu-
sion (OR, 0.12; 95%CI, 0.03-0.40; P .0001), and return
to the operating room (OR, 0.35; 95% CI, 0.14-0.76).
There was no significant difference between patching andprimary closure for risk of death (OR, 0.76; 95% CI,
0.20-2.70; P  .6), or arterial rupture (OR, 1.94; 95% CI,
0.55-6.86). None of the arterial ruptures was associated
with a fatal or major stroke. Episodes of local infection and
cranial nerve palsy were too few to enable conclusions to be
drawn.
Outcomes during long-term follow-up (>1 year),
including events during first 30 days. Six trials followed
up patients for longer than 30 days.19-24 Fifty-three arteries
(4%; 27 patch, 26 primary closure) were lost to follow-up.
For the purposes of analyses, these patients were assumed
to be event free. Patching was associated with a significant
reduction in risk for any stroke (OR, 0.31; 95% CI, 0.17-
0.63; P  .0009), ipsilateral stroke (OR, 0.31; 95% CI,
0.14-0.68; P  .001), combined stroke or death (OR,
0.54; 95% CI, 0.42-0.84; P  .004; Fig 3), and arterial
occlusion or recurrent stenosis (OR, 0.22; 95% CI, 0.13-
0.29; P  .00001; Fig 3). A similar but nonsignificant
reduction was seen in fatal strokes (OR, 0.27; 95% CI,
0.05-1.6; P  .15), and death from any cause (OR, 0.69;
95% CI, 0.49-0.99; P  .1). No pseudoaneurysms were
documented during follow-up of at least 1 year in 1141
arteries.
Description of studies of different patch materials.
Seven trials of different patch materials, reporting 1280
operations, were included. Four trials14,21,25 (Ricco, un-
published data, 1997) compared vein closure with PTFE
closure, and 3 trials26-28,30 compared vein with Dacron.
Two trials21,25 had 3 arms; saphenous vein patching, PTFE
patching, and primary closure. Four trials25-28 compared
saphenous vein harvested from the groin with synthetic
patches. One used saphenous vein from the ankle,14 1 trial
alternately used vein from the jugular and from the saphe-
nous vein at the ankle,21 and 1 trial did not specify a site.30
All meta-analyses are summarized in Fig 4. Data from the 7
trials (1280 operations) that compared vein with synthetic
patch were included.
Outcomes within 30 days of operation. The overall
risk for stroke was 1.6%, and for combined stroke and death
was 2.4%. The absolute risk for perioperative stroke (1.7%,
19 of 1120), death (1.1%, 12 of 1120), and combined
stroke and death (2.4%, 27 of 1120; Fig 5) were all low. No
significant difference was seen in risk for all strokes, ipsilat-
eral stroke, combined stroke and death, or all death.
Wound infection was nonsignificantly more common in the
vein group compared with the synthetic patch group, be-
cause of increased risk for groin wound infection.However,
there were no patch infections during the perioperative
period. Repeat operation for any reason occurred in 2.6% of
patients (33 of 1263), and showed a nonsignificant trend
toward being more common in the synthetic patch group
(OR, 1.77; 95% CI, 0.85-3.57; P  .17). Most repeat
operations were because of either patch rupture (1 in the
PTFE group, 2 in the vein group) or wound hemorrhage
(2.30%, 29 of 1263). Two of the 3 patch ruptures were
fatal, 1 in each group. There was a nonsignificant tendency
for wound hematoma to be more common in the synthetic
group (OR, 1.63; 95% CI, 0.77-3.46; P  .2)
3 pat
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630). There was no suggestion that it was more common in
either group. The absolute risk for arterial occlusion was
0.6% (6 of 1068). There was a nonsignificant trend to
suggest that acute occlusion was more common in arteries
patched with synthetic material (OR, 2.57; 95% CI, 0.59-
11.20; P  .2).
Outcomes during long-term follow-up (>1 year),
including events during first 30 days. Two trials25,26 did
not follow up patients for at least 1 year. There was no
Patch closure Primary closure
30 day results
Ipsilateral stroke 10 / 625 (1.6) 23 / 480 (4.8) 0
All death 5 / 577 (0.9) 5 / 442 (1.1) 0
Fatal stroke 1 / 577 (0.2) 2 / 442 (0.5) 0
Any stroke 9 / 577 (1.6) 20 / 442 (4.5) 0
Stroke or death 13 / 515 (2.5) 23 / 378 (6.1) 0
Return to theatre 8 / 731 (1.1) 17 / 550 (3.1) 0
Arterial occlusion 3 / 641 (0.5) 17 / 466 (3.6) 0
Cranial nerve injury 8 / 375 (2.1) 7 / 250 (2.8) 0
Long term Follow up
Ipsilateral stroke 10 / 641 (1.6) 24 / 500 (4.8) 0
All death 65 / 577 (11.3) 69 / 442 (15.6) 0
Fatal stroke 1 / 577 (0.2) 4 / 442 (0.9) 0
Any stroke 11 / 577 (1.9) 26 / 442 (5.9) 0
Stroke or death 75 / 515 (14.6) 91 / 378 (24.1) 0
Restenosis 31 / 641 (4.8) 93 / 500 (18.6) 0
Subgroup
O
R
Events / Patients
Events /
Patients
Fig 1. Summary estimates of treatment effect from al
angioplasty versus primary closure. Review included 119significant difference between PTFE and vein patching inrisk for stroke (OR, 1.31; 95% CI, 0.70-2.52; P  .71),
ipsilateral stroke (OR, 1.43; 95% CI, 0.70-2.96; P  .75),
death from all causes (OR, 0.89; 95% CI, 0.58-1.49; P 
.95), or combined stroke or death (OR, 1.04; 95% CI,
0.69-1.5; P  .99; Fig 5). However, confidence intervals
were wide in each case. Sixty-six arteries (7.3%) became
restenosed or occluded during follow-up, with no trend
favoring synthetic or vein patching (OR, 1.0; 95% CI,
0.0.6-1.62; P  .93; Fig 5). In 1 artery with a PTFE patch
an infected false aneurysm developed at 7 months, which was
0.2-0.7
0.2-2.7
0.0-4.2
0.2-0.7
0.2-0.8
0.1-0.8
0.0-0.4
0.3-2.1
0.1-0.7
0.5-1.0
0.0-1.7
0.2-0.6
0.4-0.8
0.1-0.3
95% CI
         Patch closure better               Primary closure better
Significance
1 100.1
P=.6
P=.5
P=.004
P=.007
P=.01
P=.0001
P=.7
P=.001
P=.1
P=.2
P=.0009
P=.004
P<.0001
P=.001
a-analysis outcomes from 7 trials that compared patch
ients (1281 operations)..32
.76
.38
.33
.40
.35
.12
.76
.31
.69
.19
.31
.54
.22
dds
atio
l metsuccessfully excised. There were no other late graft infections.
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n/N n/N
30 day risk of Stroke and death
Venous patch
Eikelboom 1988 3 / 66 4 / 60 0.7 0.1-3.1
Myers 1994 0 / 46 1 / 48 0.1 0.0-61.0
Vleeschauwer 1987
Synthetic patch
Katz 1994 1 / 43 2 / 44 0.5 0.0-5.7
Synthetic or venous
AbuRahma 1996 6 / 264 9 / 135 0.3 0.1-0.9
Lord 1989
Ranaboldo 1993 3 / 96 7 / 91 0.4 0.1-1.5
TOTAL 13 / 515 23 / 378 0.4 0.2-0.8
Venous patch
Eikelboom 1988 2 / 67 4 / 62 0.4 0.1-2.5
Myers 1994 0 / 46 1 / 48 0.1 0.0->10
Vleeschauwer 1987
Synthetic patch
Katz 1994 1 / 49 2 / 51 0.5 0.0-5.8
Synthetic or venous
AbuRahma 1996 4 / 264 7 / 135 0.3 0.1-1.0
Lord 1989 1 / 90 3 / 50 0.2 0.0-1.7
Ranaboldo 1993 2 / 109 6 / 104 0.3 0.1-1.5
TOTAL 10 / 625 23 / 450 0.3 0.2-0.7
Odds Ratio (95% CI)
Study OR 95% CI
No Data Available
No Data Available
No Data Available
30 day risk of Ipsilateral stroke
0 1 2 3 4 5
0 1 2 3 4 5
P(het)=.63
P(sig)=.00
P(sig)=.001
P(het)=.91
Fig 2. Thirty-day combined odds ratios for selected outcomes in patients undergoing patch versus primary closure
during carotid endarterectomy according to type of patch used. Not all end points were reported by all trials; therefore
denominators (number of operations) vary between end points.
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n/N n/N
Venous patch
Eikelboom 1988 8 / 67 17 / 62 0.4 0.1-0.9
Myers 1994 2 / 62 2 / 64 1.0 0.1-7.6
Vleeschauwer 1987 1 / 90 9 / 84 0.1 0.0-0.8
Synthetic patch
Katz 1994 0 / 49 3 / 51 0.0 0.0-17.4
Synthetic or venous
AbuRahma 1996 14 / 264 45 / 135 0.1 0.1-0.2
Ranaboldo 1993 6 / 109 17 / 104 0.3 0.1-0.8
TOTAL 31 / 641 93 / 500 0.2 0.1-0.3
Venous patch
Eikelboom 1988 23 / 66 21 / 60 1.0 0.5-2.1
Myers 1994 12 / 46 22 / 48 0.4 0.2-1.0
Vleeschauwer 1987
Synthetic patch
Katz 1994 8 / 43 12 / 44 0.6 0.2-1.7
Synthetic or venous
AbuRahma 1996 25 / 264 19 / 135 0.6 0.3-1.2
Ranaboldo 1993 7 / 96 17 / 91 0.3 0.1-0.9
TOTAL 75 / 515 91 / 378 0.6 0.4-0.8
No Data Available
Stroke and death during long-term follow up
Study OR 95% CI
0 1 2 3 4 5
Odds Ratio (95% CI)
0 1 2 3 4 5
Re-stenosis (>50%) during long-term follow up
P(sig) <.0001
P(het) = .071
P(sig) =.004
P(het) =.436
Fig 3. Long-term (1 year) combined odds ratios for selected outcomes in patients undergoing patch versus primary
closure during carotid endarterectomy according to type of patch used. Several trials included in review reported early
(30-day) and late follow-up results in separate publications. In some cases they reported different outcomes in each.
Consequently there may be greater numbers of a specific end point available during long-term follow-up than at 30
days.
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pregnated (Hemashield) Dacron with PTFE (180 patients,
200 operations).15,16 In the perioperative period (30 days)
there were 7 strokes in the Dacron group, all ipsilateral,
compared with none in the PTFE group (P  .02). There
was also increased risk for combined stroke and transient
ischemic attack (P  .47) with Dacron compared with
Synthetic Vein closure
30 day results
Ipsilateral stroke 8 / 406 (2.0) 3 / 391 (0.8) 2.6
All death 3 / 562 (0.5) 8 / 560 (1.4) 0.3
Fatal stroke 0 / 295 (0.0) 4 / 294 (1.4) 0.0
Any stroke 11 / 588 (1.9) 8 / 585 (1.4) 1.3
Stroke or death 15 / 562 (2.7) 12 / 560 (2.1) 1.2
Return to theatre 21 / 585 (3.6) 12 / 583 (2.1) 1.7
Arterial rupture 2 / 359 (0.6) 3 / 348 (0.9) 0.6
Wound infection 4 / 242 (1.7) 10 / 236 (4.2) 0.3
Cranial nerve injury 10 / 319 (3.1) 9 / 311 (2.9) 1.0
Long term Follow up
Ipsilateral stroke 17 / 389 (4.4) 12 / 387 (3.1) 1.4
All death 41 / 457 (9.0) 46 / 463 (9.9) 0.8
Any stroke 23 / 457 (5.0) 18 / 463 (3.9) 1.3
Infection 1 / 118 (0.9) 0 / 118 (0.1) 11.
Stroke or death 57 / 457 (12.5) 56 / 463 (12.1) 1.0
Restenosis 33 / 451 (7.3) 33 / 450 (7.3) 1.0
Subgroup
Od
Rat
Events /
Patients
Events /
Patients
Fig 4. Summary estimates of treatment effect from all
compared vein with synthetic patch angioplasty.PTFE. There were 2 deaths in the Dacron patch group, andnone in the PTFE group (P  .3). There were no fatal
strokes in either group. No cranial nerve palsies or wound
infections were reported. A nonsignificantly longer opera-
tion time (P  .08), but significantly longer hemostasis
time (P  .001) was found in patients who received the
PTFE patch rather than the Dacron patch. Seven patients
required repeat operation, 6 in the Dacron group and 1 in
0.7-9.9
0.1-1.4
0.0-12.7
0.5-3.4
0.6-2.7
0.9-3.6
0.1-3.9
0.1-1.2
0.4-2.7
0.7-3.0
0.6-1.4
0.7-2.5
.0-7,223.8
0.7-1.5
0.6-1.6
95% CI
                    Synthetic better                      Vein better
Significance
1 100.1
P=.27
P=.26
P=0.16
P=.65
P=.7 0
P=.17
P=.97
P=.16
P=.98
P=.75
P=.95
P=.71
P=.50
P=.99
P=.93
-analysis outcomes from 7 trials (1280 operations) that0
7
2
8
5
7
4
8
9
3
9
1
09 0
4
0
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metathe PTFE group (P  .09). All repeat explorations were
ing c
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clusion. A significant risk for recurrent stenosis or occlusion
at 30 days (P  .01) and a nonsignificant increased risk for
perioperative carotid thrombosis (P  .1) was found with
Dacron compared with PTFE. Mean follow-up was 25.5
months (range, 1-40 months), during which greater than
Synthetic Vein
n/N n/N
30 day risk of stroke or death
PTFE vs vein
AbuRhama 1996 3 / 134 3 / 130 1.0
Gonzalez 1994 2 / 39 0 / 35 19.9
Ricco 1996 1 / 53 1 / 58 1.1
Dacron vs vein
Hayes 2001 3 / 135 3 / 136 1.0
Katz 1996 3 / 107 1 / 100 2.9
O'Hara 2002 3 / 94 4 / 101 0.8
TOTAL 15 / 562 12 / 560 1.3
One year risk of arterial occlusion or r
PTFE vs vein
AbuRhama 1996 3 / 134 11 / 130 0.2
Gonzalez 1994 2 / 50 0 / 45 19.7 0
Ricco 1996 4 / 68 5 / 73 0.9
Dacron vs vein
O'Hara 2002 7 / 62 7 / 63 1.0
Naylor 2004 17 / 137 10 / 139 1.8
TOTAL 33 / 451 33 / 450 1.0
Study OR 9
Fig 5. Thirty-day and long-term (1 year) combined
synthetic patch angioplasty versus vein patch closure dur50% recurrent stenosis developed in 30% of patients withDacron patches compared with 3% of patients with PTFE
pataches (P  .001)
DISCUSSION
The results of this systematic review show a significant
and potentially clinically important trend in favor of routine
.9
10
10
.1
10
.7
.7
enosis > 50%
.9
50
.3
.1
.1
.7
 CI
0 1 2 3 4 5 6
0 1 2 3 4 5 6
P(sig)=.696
P(het)=.811
P(sig)=.93
P(het)=.06
s ratios for selected outcomes in patients undergoing
arotid endarterectomy.0.2-4
0.0->
0.1->
0.2-5
0.3->
0.2-3
0.6-2
est
0.1-0
.0- >
0.2-3
0.3-3
0.8-4
0.6-1
5%
oddpatching versus primary closure in terms of both short-term
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stroke, and any stroke or death. However, the results may
still be unreliable, because of the presence of significant
methodologic flaws in many of the included trials. The
trials were also generally too small to achieve adequate
statistical power, and none could be analyzed on a true
intention-to-treat basis, in part because there were signifi-
cant losses to follow-up. However, there were no signifi-
cant differences in numbers lost to follow-up between
treatment groups in any of the studies. Consequently, our
assumption that patients who were lost to follow-up did
not have an outcome event should not have introduced
major bias. Furthermore, analysis of quasi-randomized tri-
als separately from truly randomized studies did not signif-
icantly influence any results.
Patching also appears to significantly reduce the risk for
acute occlusion and long-term recurrent stenosis, com-
pared with primary closure. However, these findings may
be less useful than data on clinically important outcomes
such as stroke. Acute occlusion, though undesirable, is not
always associated with stroke. Similarly, recurrent stenosis
detected at routine duplex scanning may not be clinically
important. In some cases remodeling of the arterial wall
after endarterectomy can be mistaken for stenosis, and in
other cases spontaneous regression of duplex ultrasound
scan–defined stenosis has occurred.19,32 Moreover, recur-
rent stenosis may be associated with lower risk for neuro-
logic symptoms, compared with primary stenosis.32
Most surgeons agree that carotid patching has a role in
CEA, because they are faced with situations in which this
type of closure is either unavoidable or positively desirable
(eg, artery with very narrow internal diameter or very long
plaque).22 However, it is unclear how frequently such
situations arise, and how narrow an artery should be before
it must be patched. For example, only 3 trials in this review
excluded narrow arteries on the grounds that they must be
patched. In the other trials, crossover from primary closure
to patching was required in few patients because the artery
was deemed too narrow for primary closure. There is di-
vided opinion on how often patching is required; some
surgeons use it all the time, others use it rarely or never.4
The trials of patch versus no patch included in this review
tested the policy of routinely patching all arteries against a
policy of never patching in those patients with no definite
indication for a patch. A policy of selective patching of only
those arteries thought to require a patch at the time of
operation compared with no patching has not been tested
in RCTs. It is possible that if patching is effective its benefit
may be restricted to narrow arteries. It was not possible to
test this hypothesis, because the results of the trials were not
reported according to degree of narrowing of the artery.
Despite more than 1200 patients randomized, there
were still insufficient data to enable definite conclusions
about the optimal patch type. There are no obvious differ-
ences in the risk for stroke or death in patients receiving
synthetic or vein patches, either perioperatively or during
long-term follow-up, or evidence to support the belief that
synthetic patches are associated with lower risk for patchrupture. The risk for major arterial complications such as
rupture or infection was low (1%) in both groups. Any
trials designed to reliably detect reduction in risk for rup-
ture with synthetic patches would therefore need to be
enormous, and even if the risk for rupture were less with
synthetic patches, the absolute benefits would be small. For
example, if we assume a baseline risk for rupture of 0.6%,
more than 10,000 arteries would be needed for an 80%
chance of detecting a 50% reduction in the relative risk for
rupture, and this would still prevent only 1 rupture in every
350 operations.
Although there is little reliable evidence to guide sur-
geons as to which patch material to use, synthetic patches
offer the advantage of sparing the morbidity (eg, poor
wound healing, pain) and time associated with vein harvest-
ing and ensure that vein is available for future coronary
bypass grafting if required. However, use of PTFE in
patching may increase operation time by several minutes,
mainly because of increased bleeding through the suture
holes. This may be less of a problemwithDacron patches.33
In addition, the trial by Carney and Lilly33 suggests that
surgeons prefer the handling qualities of Dacron or vein to
PTFE, which they found less compliant. Dacronmay there-
fore be preferable to PTFE, although some believe it carries
a greater risk for thrombosis25 and may be more prone to
infection.34 Furthermore, the newer versions of PTFE may
be more hemostatic than previously, and the only good,
quality randomized trial that has compared the use of PTFE
and Dacron in CEA found a significant benefit of PTFE
over collagen-impregnated (Hemashield) Dacron grafts in
terms of 30-day stroke rate, combined transient ischemic
attack and stroke rate, and recurrent stenosis and long-term
recurrent stenosis rates.15,16 However, it also noted longer
hemostasis time with PTFE (14.4 minutes vs 3.4 minutes;
P  .001).
At present, most vascular surgeons do not routinely use
patching in all patients undergoing CEA. However, despite
the limitations of the data, the results of this review appear
to support a recommendation in favor of routine patching,
although more conclusive evidence is required because
numbers are still small. Individual surgeons, and patients,
may still interpret the evidence differently, and therefore it
is up to each surgeon to decide whether to patch routinely.
It is also relevant to note that many surgeons are now
performing eversion CEA as opposed to the “standard”
longitudinal arteriotomy technique. This technique re-
moves the need for patching, and should be borne in mind
during design of further trials of carotid patching. This
technique has not been studied in this review, to prevent
overly confusing the results.
The use of selective patching (eg, in very narrow arter-
ies) has not been studied in RCTs; thus, although it is likely
to be required on occasion, no clear indications for selective
patching can be given. The results of this review do not
support the use of vein over synthetic patch material in
CEA. The decision as to which type of patch to use, if any,
remains a matter of individual preference. However, if
synthetic material is used, the currently available (limited)
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 6 Bond et al 1135evidence from a single trial appears to show benefits from
PTFE as opposed to Dacron material.
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